BIOA (BioAge Labs, Inc) Earnings growth in current year

BioAge Labs, Inc. (BIOA) is implementing AI platforms and robotics for molecular target discovery, reinforcing its strategy to combat obesity through the study of aging. The success of BioAge Labs, Inc. (BIOA) depends on clinical trials and strategic alliances, despite fierce competition with industry behemoths. The year-over-year growth rate of net income per share clearly demonstrates the trend, where the value -16.00 represents the current metric.

BIOA: BioAge Labs, Inc. Earnings per share growth in current year 09/27/2024 - 11/15/2026

Financial and market metric breakdowns for BioAge Labs (BIOA)

- share price and expert price forecast:

Price BioAge Labs Inc.|BIOA - Analyst Consensus Forecast

- business market valuation indicators:

Market Capitalization BioAge Labs, Inc.|BIOA - Enterprise Value

- book capitalization data:

Net Assets per Single Share BioAge Labs, Inc.|BIOA - Company Book Value|Market-to-Book Ratio bioagelabs.com|BIOA - Aggregate Company Assets

- debt burden and liquidity indicators:

- earnings and valuation multiples information:

BIOA - Net Profit|Company Profit Forecast BioAge Labs, Inc.|BIOA - Price to Earnings Ratio|Projected Price to Earnings Ratio BioAge Labs, Inc.|BIOA - PEG Multiple|EV/EBITDA Multiple BioAge Labs, Inc.|BIOA - Operating profit EBITDA|Net earnings per share for the trailing year BioAge Labs, Inc.|BIOA - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months bioagelabs.com|BIOA - Net earnings per share growth this year|Expected earnings per share trend next year BioAge Labs, Inc.

- revenue and sales proceeds data:

BIOA - Company Revenue|Company Projected Revenue BioAge Labs Inc.|BIOA - P/S Multiple|Forward P/S Multiple BioAge Labs, Inc.

Basic company analysis:BIOA - BioAge Labs, Inc

The long-term sustainability of BioAge Labs, Inc. (BIOA) is determined by the balance of debt obligations and yield dynamics, where the relative annual growth of net earnings per share measures the efficiency of business capitalization compared to previous periods. A positive trend in this indicator confirms the solvency of BioAge Labs, Inc., reflecting the financial impact of synergies from joint appetite inhibitor developments with global pharmaceutical partners.

Main competitors